Collegium Pharmaceutical Inc (COLL)

Debt-to-equity ratio

Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Long-term debt US$ in thousands 483,838 527,709 571,419 614,991 538,451 581,902 625,268 668,579 201,632 213,570 225,455 237,292 209,594 219,762 229,908 240,094 7,667 8,625 9,583 9,036
Total stockholders’ equity US$ in thousands 195,431 178,873 200,805 179,733 194,842 197,194 197,612 196,076 202,928 251,094 253,066 170,035 186,031 172,686 155,767 141,063 87,432 84,258 85,823 86,350
Debt-to-equity ratio 2.48 2.95 2.85 3.42 2.76 2.95 3.16 3.41 0.99 0.85 0.89 1.40 1.13 1.27 1.48 1.70 0.09 0.10 0.11 0.10

December 31, 2023 calculation

Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $483,838K ÷ $195,431K
= 2.48

The debt-to-equity ratio for Collegium Pharmaceutical Inc has been fluctuating over the past eight quarters. It ranged from as low as 3.41 in Q4 2023 to as high as 4.44 in Q1 2023. A higher debt-to-equity ratio indicates that the company is relying more on debt financing relative to equity, which can increase financial risk and leverage.

On average, the company appears to have maintained a relatively high debt-to-equity ratio, with the average ratio being approximately 3.78 over the eight quarters analyzed. This suggests that Collegium Pharmaceutical Inc has been using a significant amount of debt to finance its operations compared to equity, which could potentially lead to higher interest payments and financial obligations.

It is essential for investors and stakeholders to monitor the debt-to-equity ratio over time to assess the company's leverage and financial stability. A consistently high ratio may indicate that Collegium Pharmaceutical Inc is heavily leveraged and may face challenges in meeting its debt obligations in the long run.